QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery (neoadjuvant therapy) can improve outcomes for people with triple-negative breast cancer — an aggressive subtype that lacks the three main treatment targets (estrogen, progesterone receptors, and HER2). **You may be eligible if...** - You are 18 or older - You have newly diagnosed triple-negative breast cancer (confirmed by biopsy) at clinical stage II or III - Your tumour is at least 2 cm in size, or you have confirmed lymph node involvement - You have not received any prior cancer treatment - You are in good health (ECOG 0–1) with adequate organ function - You are not pregnant and use effective contraception **You may NOT be eligible if...** - You have stage IV (metastatic) breast cancer - You have had chemotherapy, immunotherapy, or radiation in the past 12 months - You have had another invasive cancer in the past 5 years (with some exceptions) Talk to your doctor to see if this trial is right for you.